secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-117256
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara: $83M cash, royalty deal up to $40M, oral DFK Phase 3 readouts 2023-2026
-----------------------------------------------------------------------------

- Cash $83M as of Sep 30, 2023; royalty sale with HCRx for up to $40M ($37.5M expected Q4 2023).
- KORSUVA injection launched with CSL Vifor/Fresenius; approved in US, EU, Japan; TDAPA expires Mar 31, 2024.
- Oral DFK Phase 3: KIND1 AD topline Dec 2023; KICK1&2 CKD topline 2H2024; KOURAGE1 NP topline 2H2024.
- No debt, 54M shares outstanding, cash runway into 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923117256/0001104659-23-117256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923117256/tm2330513d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer